TrialCancer science2018

Phase II trial of biweekly cetuximab and irinotecan as third-line therapy for pretreated KRAS exon 2 wild-type colorectal cancer.

Hiroki Osumi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.